Über
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
Hauptsitz
San Francisco, California, USA
Gegründet
2013
Typ
Labor
Ökosysteme
1
Rechtliche Identität
- Rechtlicher Name
- Calico Life Sciences LLC
- Status
- Aktiv
- Geprüft am
- 2026-08-30
- Nächste Prüfung
- 2026-11-30
Mission
“Harness advanced technologies to increase human healthspan.”
Schwerpunkte
Aging biologyDrug discoverySenolyticsCellular reprogrammingBiomarkers
Beteiligung an Ökosystemen
Strategische Roadmap
2025 Q4
● LaufendABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
Langlebigkeit & Anti-Aging
2026 Q4
◯ GeplantCombination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
Langlebigkeit & Anti-Aging
2028 Q2
◯ GeplantAge reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
Langlebigkeit & Anti-Aging